Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01304797|
Recruitment Status : Unknown
Verified January 2017 by Merrimack Pharmaceuticals.
Recruitment status was: Active, not recruiting
First Posted : February 25, 2011
Last Update Posted : January 6, 2017
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Actual Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||January 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. (64)Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.